Branka Grubor-Bauk

APrf Branka Grubor-Bauk

Internal Grant-Funded Researcher (D)

School of Medicine

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

A/Prof Grubor-Bauk is the Head of Viral Immunology Group at the Adelaide Medical School. She trained as a virologist, immunologist, and vaccine scientist and after postdoctoral training and a period in Biotech, she now leads a collaborative research program which encompasses discovery and translational science components. 

Multidisciplinary approach of our group covers areas of translational immunology and vaccine development. We collaborate and work closely with clinicians in the areas of long COVID, severe viral respiratory infections, sepsis and vaccination responses in vulnerable populations. Our group is also focussed on development of novel vaccines and vaccine platforms against various pathogens, for human and veterinary use. Recently we have expanded our research portfolio into development of novel mRNA and saRNA vaccines in cancer therapy, as well as in prevention of bacterial infections.

Our group has various commercial research partnerships, with an aim to develop solutions with clinical application. 

Student projects

We have various student projects available for Honours, Masters and PhD studies. The projects cover vaccine development (mRNA, saRNA, rAAV) with options for cross-discipline and industry collaborations. Please see the list below for currently available projects. 

Prospective students can contact Branka directly via email. 

Please note: 

Prerequisite: Students must have sound knowledge of immunology in order to undertake these projects. 

 

Available projects: 

1) Development of multivalent mRNA and saRNA vaccines 

2) Novel mRNA-LNP formulations for optimal vaccine immunogenicity 

3) mRNA-LNP biodistribution and tissue targeting 

4) Novel mRNA vaccines in cancer therapy

5) Development of mRNA vaccines for induction of gamma delta T cell immunity 

6) Liver immunobiology in HCV vaccine development 

7) mRNA vaccines against Staph aureus

8) Murray Valley encephalitis virus vaccine development

9) Biomarkers of sepsis and in hospital mortality in ICU patients

10) Biomarkers of Long COVID

11) Immunopathology of Long COVID

11) Innate immunity and LNP/mRNA formulations

12) Impact of prior dengue virus infection on Zika virus infection during pregnancy

 

Language Competency
English -
Serbian -

Date Institution name Country Title
2007 University of Adelaide, Adelaide Australia PhD
1999 University of Adelaide, Adelaide Australia Bachelor of Health Sciences (Honours)
1998 University of Adelaide, Adelaide Australia Bachelor of Science

Year Citation
2026 Santos, R., Mekonnen, Z. A., Yeow, A. E. L., Whelan, D. M., Al-Delfi, Z., Eyre, N. S., . . . Grubor-Bauk, B. (2026). Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika virus. NPJ VACCINES, 11(1), 14 pages.
DOI
2025 Hosseini-Kharat, M., Bremmell, K. E., Grubor-Bauk, B., & Prestidge, C. A. (2025). Enhancing non-viral DNA delivery systems: Recent advances in improving efficiency and target specificity. Journal of Controlled Release, 378, 170-194.
DOI Scopus15 WoS16 Europe PMC9
2025 Carolin, A., Bishop, C. R., Yan, K., Grubor-Bauk, B., Plummer, M. P., Tang, B., . . . Suhrbier, A. (2025). Evidence from COVID-19 Patients and Murine Studies for a Continuing Trend Towards Targeting of Nasopharyngeal Ciliated Epithelial Cells by SARS-CoV-2 Omicron Sublineages. Viruses, 17(12), 18 pages.
DOI
2025 Hosseini-Kharat, M., Wignall, A., Mekonnen, Z. A., Ung, B. S. -Y., Chereda, B., Bremmell, K. E., . . . Prestidge, C. A. (2025). Microfluidic Optimization of PEI-Lipid Hybrid Nanoparticles for Efficient DNA Delivery and Transgene Expression. Pharmaceutics, 17(4), 454.
DOI Scopus2 WoS2
2025 Perkins, G. B., Tunbridge, M. J., Chai, C. S., Hope, C. M., Lip Yeow, A. E., Salehi, T., . . . Coates, P. T. (2025). mTOR Inhibitors and Vaccine Response in Kidney Transplant Recipients.. J Am Soc Nephrol, 36(11), 2213-2227.
DOI Scopus2 WoS1 Europe PMC1
2025 Garcia-Valtanen, P., Yeow, A. E. L., Mekonnen, Z. A., Whelan, D. M., Santos, R., Al-Delfi, Z., . . . Grubor-Bauk, B. (2025). Thermostable unit solid dose formulations for subcutaneous administration of DNA vaccines. Molecular Therapy Nucleic Acids, 36(3), 10 pages.
DOI
2025 Messina, N. L., Germano, S., Chung, A. W., van de Sandt, C. E., Stevens, N. E., Allen, L. F., . . . BRACE Trial Consortium Group. (2025). Effect of Bacille Calmette-Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination. Clinical & Translational Immunology, 14(1), e70023-1-e70023-18.
DOI Scopus3 WoS3 Europe PMC3
2025 Liu, D., Wang, X., Xu, L., Al-Delfi, Z. N. S., Mekonnen, Z. A., Gao, S., . . . Zhao, C. -X. (2025). Screening lipid nanoparticles using DNA barcoding and qPCR. Colloids and Surfaces B: Biointerfaces, 251, 114598-1-114598-11.
DOI Scopus5 WoS3 Europe PMC1
2024 Messina, N. L., Germano, S., McElroy, R., Bonnici, R., Grubor-Bauk, B., Lynn, D. J., . . . Spotswood, J. (2024). Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines - an exploratory sub-study of the BRACE trial. eBioMedicine, 103, 105100-1-105100-16.
DOI Scopus9 WoS8 Europe PMC6
2024 Singer, J., Tunbridge, M. J., Shi, B., Perkins, G. B., Chai, C. S., Salehi, T., . . . Chadban, S. J. (2024). Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial. Vaccines, 12(6), 608-1-608-20.
DOI Scopus6 WoS4 Europe PMC3
2024 Sinclair, J. E., Vedelago, C., Ryan, F. J., Carney, M., Redd, M. A., Lynn, M. A., . . . Short, K. R. (2024). Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function. Nature Microbiology, 9(12), 3135-3147.
DOI Scopus11 Europe PMC9
2023 Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., . . . Lynn, D. J. (2023). A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines.. Cell Reports Medicine, 4(3), 100971-1-100971-26.
DOI Scopus37 WoS36 Europe PMC36
2023 Zhang, W., Kedzierski, L., Chua, B. Y., Mayo, M., Lonzi, C., Rigas, V., . . . Christensen, B. (2023). Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.. Nature Immunology, 24(6), 966-978.
DOI Scopus21 WoS21 Europe PMC24
2023 Williams, C. M. D., Noll, J. E., Bradey, A. L., Duggan, J., Wilczek, V. J., Masavuli, M. G., . . . Panagopoulos, V. (2023). Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma. British Journal of Haematology, 203(4), 614-624.
DOI Scopus5 WoS5 Europe PMC5
2023 Wijesundara, D. K., Yeow, A., McMillan, C. L. D., Choo, J. J. Y., Todorovic, A., Mekonnen, Z. A., . . . Muller, D. A. (2023). Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine. Molecular Therapy Nucleic Acids, 34, 102056-1-102056-10.
DOI Scopus10 WoS9 Europe PMC10
2022 Ryan, F., Norton, T., McCafferty, C., Blake, S., Stevens, N., James, J., . . . Lynn, D. (2022). A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses.
DOI
2022 Balachandran, H., Phetsouphanh, C., Agapiou, D., Adhikari, A., Rodrigo, C., Hammoud, M., . . . Bull, R. A. (2022). Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Cell Reports, 38(6), 19 pages.
DOI Scopus38 WoS38 Europe PMC39
2022 Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Yeow, A. E. L., . . . Lynn, D. J. (2022). Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Medicine, 20(1), 26-1-26-23.
DOI Scopus211 WoS205 Europe PMC207
2022 Perkins, G. B., Tunbridge, M., Salehi, T., Chai, C. S., Kireta, S., Johnston, J., . . . Coates, P. T. (2022). Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. Kidney International, 101(5), 1077-1080.
DOI Scopus11 WoS10 Europe PMC10
2022 Garcia-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., . . . Grubor-Bauk., B. (2022). SARS-CoV-2 Omicron variant escapes neutralising antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.. Cell Reports Medicine, 3(6), 100651-1-100651-17.
DOI Scopus34 WoS33 Europe PMC32
2022 Tunbridge, M., Perkins, G. B., Singer, J., Salehi, T., Ying, T., Grubor-Bauk, B., . . . Coates, P. T. (2022). Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients.. Trials, 23(1), 780-1-780-12.
DOI Scopus7 WoS7 Europe PMC5
2022 Adhikari, A., Abayasingam, A., Rodrigo, C., Agapiou, D., Pandzic, E., Brasher, N. A., . . . COSIN Study Group. (2022). Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection.. J Immunol, 209(8), 1499-1512.
DOI Scopus2 WoS2 Europe PMC2
2021 Abayasingam, A., Balachandran, H., Agapiou, D., Hammoud, M., Rodrigo, C., Keoshkerian, E., . . . COSIN study group. (2021). Long-term persistence of RBD-positive memory B cells encoding neutralising antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2(4), 100228-1-100228-14.
DOI Scopus58 WoS56 Europe PMC70
2021 Garcia-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., . . . Grubor-Bauk, B. (2021). COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection.
DOI
2020 Gummow, J., Masavuli, M., Mekonnen, Z. A., Li, Y., Wijesundara, D. K., Shrestha, A. C., . . . Grubor-Bauk, B. (2020). Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus. Vaccines, 8(1), 1-15.
DOI Scopus11 WoS9 Europe PMC7
2020 Fenix, K., Wijesundara, D. K., Cowin, A. J., Grubor-Bauk, B., & Kopecki, Z. (2020). Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis.. International Journal of Molecular Sciences, 21(19), 7228-1-7228-13.
DOI Scopus32 WoS29 Europe PMC25
2020 Mekonnen, Z. A., Masavuli, M. G., Yu, W., Gummow, J., Whelan, D. M., Al-Delfi, Z., . . . Grubor-Bauk, B. (2020). Enhanced T cell responses induced by a necrotic dendritic cell vaccine, expressing HCV NS3. Front Microbiol, 11(559105), 1-13.
DOI Scopus8 WoS6 Europe PMC5
2019 Roy, S., Jaeson, M., Li, Z., Mahboob, S., Jackson, R., Grubor-Bauk, B., . . . Ranasinghe, C. (2019). Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. Vaccine, 37(10), 1266-1276.
DOI Scopus18 WoS16 Europe PMC16
2019 Mekonnen, Z. A., Grubor-Bauk, B., Masavuli, M. G., Shrestha, A. C., Ranasinghe, C., Bull, R. A., . . . Wijesundara, D. K. (2019). Toward DNA-based T-cell mediated vaccines to target HIV-1 and hepatitis C virus: approaches to elicit localized immunity for protection. Frontiers in Cellular and Infection Microbiology, 9(APR), 1-8.
DOI Scopus14 WoS10 Europe PMC9
2019 Shrestha, A. C., Wijesundara, D. K., Masavuli, M. G., Mekonnen, Z. A., Gowans, E. J., & Grubor-Bauk, B. (2019). Cytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines. Vaccines, 7(2), 14 pages.
DOI Scopus12 WoS12 Europe PMC10
2019 Masavuli, M. G., Wijesundara, D. K., Underwood, A., Christiansen, D., Earnest-Silveira, L., Bull, R., . . . Grubor-Bauk, B. (2019). A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice. Frontiers in immunology, 10(MAY), 1-19.
DOI Scopus34 WoS30 Europe PMC28
2019 Christiansen, D., Earnest-Silveira, L., Grubor-Bauk, B., Wijesundara, D. K., Boo, I., Ramsland, P. A., . . . Torresi, J. (2019). Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Scientific Reports, 9(1), 1-13.
DOI Scopus57 WoS52 Europe PMC48
2019 Mekonnen, Z. A., Grubor-Bauk, B., English, K., Leung, P., Masavuli, M. G., Shrestha, A. C., . . . Wijesundara, D. K. (2019). Single-dose vaccination with a hepatotropic adeno-associated virus efficiently localizes T cell immunity in the liver with the potential to confer rapid protection against Hepatitis C virus. Journal of Virology, 93(19), e00202-19-1-e00202-19-19.
DOI Scopus17 WoS19 Europe PMC18
2019 Grubor-Bauk, B., Wijesundara, D. K., Masavuli, M., Abbink, P., Peterson, R. L., Prow, N. A., . . . Gowans, E. J. (2019). NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice.. Sci Adv, 5(12), eaax2388.
DOI Scopus66 WoS57 Europe PMC56
2018 Christiansen, D., Earnest-Silveira, L., Chua, B., Meuleman, P., Boo, I., Grubor-Bauk, B., . . . Torresi, J. (2018). Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. Scientific Reports, 8(1), 6483-1-6483-13.
DOI Scopus41 WoS35 Europe PMC34
2018 Wijesundara, D., Gummow, J., Li, Y., Yu, W., Quah, B., Ranasinghe, C., . . . Grubor-Bauk, B. (2018). Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. Journal of Virology, 92(8), 1-15.
DOI Scopus21 WoS22 Europe PMC21
2018 Christiansen, D., Earnest-Silveira, L., Chua, B., Boo, I., Drummer, H. E., Grubor-Bauk, B., . . . Torresi, J. (2018). Antibody responses to a quadrivalent Hepatitis C viral-like particle vaccine adjuvanted with Toll-like receptor 2 agonists. Viral Immunology, 31(4), 1-6.
DOI Scopus11 WoS10 Europe PMC10
2017 Wijesundara, D., Yu, W., Quah, B., Eldi, P., Hayball, J., Diener, K., . . . Grubor-Bauk, B. (2017). Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner. Scientific Reports, 7(1), 8530-1-8530-8.
DOI Scopus8 WoS9 Europe PMC9
2017 Wijesundara, D., Ranasinghe, C., Grubor-Bauk, B., & Gowans, E. (2017). Emerging targets for developing T cell-mediated vaccines for human immunodeficiency virus (HIV)-1. Frontiers in Microbiology, 8(OCT), 2091-1-2091-7.
DOI Scopus12 WoS11 Europe PMC9
2017 Masavuli, M., Wijesundara, D., Torresi, J., Gowans, E., & Grubor-Bauk, B. (2017). Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C. Frontiers in Microbiology, 8(DEC), 11 pages.
DOI Scopus41 WoS31 Europe PMC30
2016 Canavese, M., Wijesundara, D., Maddern, G. J., Grubor-Bauk, B., & Hauben, E. (2016). Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: From immune evasion to carcinogenesis. Clinical and Translational Immunology, 5(10), 5 pages.
DOI Scopus13 WoS9 Europe PMC7
2016 Canavese, M., Wijesundara, D., Maddern, G., Grubor-Bauk, B., & Hauben, E. (2016). Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis.. Clin Transl Immunology, 5(10), 1-6.
DOI WoS13 Europe PMC13
2016 Tomusange, K., Wijesundara, D., Gummow, J., Wesselingh, S., Suhrbier, A., Gowans, E., & Grubor-Bauk, B. (2016). Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. Scientific Reports, 6(1), 36658 -1-36658-11.
DOI Scopus10 WoS10 Europe PMC11
2016 Grubor-Bauk, B., Yu, W., Wijesundara, D., Gummow, J., Garrod, T., Brennan, A., . . . Gowans, E. (2016). Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Therapy, 23(1), 26-37.
DOI Scopus25 WoS24 Europe PMC24
2016 Tomusange, K., Wijesundara, D., Gummow, J., Garrod, T., Li, Y., Gray, L., . . . Gowans, E. (2016). A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice. Scientific Reports, 6(1), 29131-1-29131-10.
DOI Scopus19 WoS19 Europe PMC18
2016 Jorritsma, S., Gowans, E., Grubor-Bauk, B., & Wijesundara, D. (2016). Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine, 34(46), 5488-5494.
DOI Scopus117 WoS108 Europe PMC96
2015 Tomusange, K., Yu, W., Suhrbier, A., Wijesundara, D., Grubor-Bauk, B., & Gowans, E. (2015). Engineering human rhinovirus serotype-A1 as a vaccine vector. Virus Research, 203, 72-76.
DOI Scopus7 WoS6 Europe PMC4
2015 Gummow, J., Li, Y., Yu, W., Garrod, T., Wijesundara, D., Brennan, A., . . . Gowans, E. (2015). A multiantigenic DNA vaccine that induces broad hepatitis C virus-specific T-Cell responses in mice. Journal of Virology, 89(15), 7991-8002.
DOI Scopus23 WoS25 Europe PMC23
2014 Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 10(12), 3576-3578.
DOI WoS2
2014 Yu, W., Grubor-Bauk, B., Gargett, T., Garrod, T., & Gowans, E. (2014). A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice. Vaccine, 32(27), 3409-3416.
DOI Scopus17 WoS16 Europe PMC12
2014 Gargett, T., Grubor-Bauk, B., Miller, D., Garrod, T., Yu, S., Wesselingh, S., . . . Gowans, E. (2014). Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. Clinical and Translational Immunology, 3(6), e18-1-e18-7.
DOI Scopus23 WoS20 Europe PMC20
2014 Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. Human vaccines & immunotherapeutics, 10(12), 3576-3578.
DOI Scopus3 Europe PMC3
2014 Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T., & Gowans, E. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.. Human vaccines & immunotherapeutics, 10(9).
2014 Garrod, T., Gargett, T., Yu, W., Major, L., Burrell, C., Wesselingh, S., . . . Gowans, E. (2014). Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. Virus Research, 192, 25-33.
DOI Scopus6 WoS6 Europe PMC6
2014 Garrod, T., Grubor-Bauk, B., Gargett, T., Li, Y., Miller, D., Yu, W., . . . Gowans, E. (2014). DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency. European Journal of Immunology, 44(7), 1992-2002.
DOI Scopus24 WoS21 Europe PMC19
2014 Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T., & Gowans, E. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency. Human Vaccines and Immunotherapeutics, 10(9), 2679-2683.
DOI Scopus10 WoS11 Europe PMC9
2014 Gargett, T., Grubor-Bauk, B., Garrod, T., Yu, W., Miller, D., Major, L., . . . Gowans, E. (2014). Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunology and Cell Biology, 92(4), 359-367.
DOI Scopus24 WoS25 Europe PMC24
2008 Grubor-Bauk, B., Arthur, J., & Mayrhofer, G. (2008). Importance of NKT Cells in Resistance to Herpes Simplex Virus, Fate of Virus-Infected Neurons, and Level of Latency in Mice. Journal of Virology, 82(22), 11073-11083.
DOI Scopus44 WoS43 Europe PMC40
2003 Grubor-Bauk, B., Simmons, A., Mayrhofer, G., & Speck, P. (2003). Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα14-Jα 281 TCR. Journal of Immunology, 170(3), 1430-1434.
DOI Scopus175 WoS166 Europe PMC155
- Abayasingam, A., Balachandran, H., Agapiou, D., Rodrigo, C., Keoshkerian, E., Li, H., . . . Group, C. O. S. I. N. S. (n.d.). Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2. SSRN Electronic Journal.
DOI

Year Citation
2017 Tomusange, K., Wijesundara, D., Gowans, E., & Grubor-Bauk, B. (2017). Human rhinovirus-A1 as an expression vector. In M. C. Ferran, & G. R. Skuse (Eds.), Recombinant Virus Vaccines: Methods and Protocols (Vol. 1581, pp. 181-201). UK: Humana Press.
DOI

Year Citation
2025 Grubor-Bauk, B., Masavuli, M. G., Mekonnen, Z. A., Whelan, D. M., Yeow, A. E. L., Santos, R., . . . O'connor, D. H. (2025). A Safer Alternative: Development of multivalent T cell vaccine against Zika virus \. In JOURNAL OF IMMUNOLOGY Vol. 214 (pp. 165-166). HI, Honolulu: OXFORD UNIV PRESS.
DOI
2024 Chai, C. S., Perkins, G. B., Tunbridge, M., Hope, C., Yeow, A., Salehi, T., . . . Coates, T. (2024). Rapamycin diversifies SARS-CoV-2 specific T cell memory with stem cell phenotype in immunosuppressed kidney transplant recipients. In Abstracts of the 30th International Congress of The Transplantation-Society (TTS, 2024) as published in Transplantation Vol. 108 (pp. 89). Istanbul, Turkey: Lippincott, Williams & Wilkins.
2024 Sheng Chai, C., Boord Perkins, G., Tunbridge, M., Hope, C., Yeow, A., Salehi, T., . . . Coates, T. (2024). Rapamycin diversifies SARS-CoV-2 specific T cell memory with stem cell phenotype in immunosuppressed kidney transplant recipients.. In TRANSPLANTATION Vol. 108 (pp. 1 page). TURKEY, Istanbul: LIPPINCOTT WILLIAMS & WILKINS.
DOI
2022 Perkins, G., Tunbridge, M., Salehi, T., Chai, C. S., Hope, C. M., Garcia-Valtanen, P., . . . Coates, A. O. T. (2022). MTOR Inhibitors Promote Highly Functional T Cell Immunity in Kidney Transplant Recipients Vaccinated Against COVID-19. In TRANSPLANTATION Vol. 106 (pp. S223). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2022 Tunbridge, M. J., Perkins, G., Salehi, T., Grubor-Bauk, B., Sim, B., Ying, T., . . . Coates, P. T. (2022). A Prospective Randomised, Controlled Trial Switching Sirolimus for Mycophenolate to Enhance Immunological Responses to Third Dose COVID-19 Vaccination in Kidney Transplant Recipients with Poor Baseline Humoral Immunity. In AMERICAN JOURNAL OF TRANSPLANTATION Vol. 22 (pp. 1095). ELECTR NETWORK: WILEY.
2022 Perkins, G. B., Tunbridge, M., Salehi, T., Chai, C., Hope, C. M., Garcia-Valtanen, P., . . . Coates, P. (2022). Sirolimus Use is Associated with an Improved Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients. In AMERICAN JOURNAL OF TRANSPLANTATION Vol. 22 (pp. 873). WILEY.
2021 Liu, Y., Yue, J., Shi, P., Wang, Y., Gao, H., Feng, B., . . . Li, H. (2021). A Deep Learning Method for LiDAR Bathymetry Waveforms Processing. In Z. Zhang (Ed.), 2021 INTERNATIONAL CONFERENCE ON NEURAL NETWORKS, INFORMATION AND COMMUNICATION ENGINEERING Vol. 11933 (pp. 7 pages). PEOPLES R CHINA, Qingdao: SPIE-INT SOC OPTICAL ENGINEERING.
DOI WoS2
2016 Wijesundara, D., Grubor-Bauk, B., Gargett, T., Yu, W., & Gowans, E. (2016). A cytolytic DNA vaccine to target cross-presentation of dendritic cells. In EUROPEAN JOURNAL OF IMMUNOLOGY Vol. 46 (pp. 1060-1061). Melbourne, AUSTRALIA: WILEY-BLACKWELL.

Year Citation
2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of 12th Annual Scientific Meeting of the Australian Centre for HIV and Hepatitis Virology.
2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of Adelaide Immunology Retreat. Nuriootpa.
2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of Florey Postgraduate Research Conference.
2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Enhancing the immunogenicity of HCV vaccines by fusing E1/E2 to the IMX313P multimerization technology. Poster session presented at the meeting of 24th International Symposium on Hepatitis C Virus and Related Viruses. Hyannis, Cape Cod, Massachusetts, USA.
2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccines encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day. Adeleide, Australia.
2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Enhancing the immunogenicity of HCV vaccines by fusing E1/E2 to the IMX313P oligomerisation technology. Poster session presented at the meeting of 9th Australasian Virology Society Meeting.
2016 Tomusange, K., Wijesundara, D., Gummow, J., Gowans, E. J., & Grubor-Bauk, B. (2016). Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits protective HIV-specific immune responses. Poster session presented at the meeting of Abstracts of the 2016 Conference on HIV Research for Prevention (HIV R4P), as published in Aids Research and Human Retroviruses. Chicago, IL: Mary Ann Liebert.
DOI
2016 Khamis, T., Wijesundara, D., Gummow, J., Garrod, T., Li, Y., Gray, L., . . . Gowans, E. (2016). HIV-Tat Fused to the Oligomerisation Domain of the C4-binding Protein Is Highly Immunogenic and Controls EcoHIV Challenge in Mice. Poster session presented at the meeting of AIDS RESEARCH AND HUMAN RETROVIRUSES. Chicago, IL: MARY ANN LIEBERT, INC.
2016 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2016). A novel DNA-based virus-like particle (VLP) vaccine against hepatitis C.. Poster session presented at the meeting of Florey Postgraduate Research Conference.
2016 Masavuli, M. G., Wijesundara, D. W., Grubor-Bauk, B., & Gowans, E. J. (2016). A DNA-based virus-like particle (VLP) vaccine against the hepatitis C virus. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day. Adelaide.
2015 Masavuli, M. G., Grubor-Bauk, B. G., Wijesundara, D. K., & Gowans, E. J. (2015). A novel DNA-based virus-like particle (VLP) vaccine for hepatitis C virus. Poster session presented at the meeting of Florey Postgraduate Research Conference. AdelaIide.
2015 Masavuli, M. G., Wijesundara, D. K., grubor-bauk, B., & gowans, E. G. (2015). A novel DNA-based virus-like particle vaccine for hepatitis C virus. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day 2015. Adelaide.
2013 Loveland, B. E., Latour, P., Roberts, S. K., Gordon, A., Kemp, W., Kitson, M., . . . Gowans, E. J. (2013). A Phase I clinical trial of cellular immunotherapy for persistent Hepatitis C infection. Poster session presented at the meeting of Clinical and Experimental Pharmacology and Physiology. Hangzhou, Peoples Republic of China: Wiley-Blackwell.

Year Citation
2018 Masavuli, M. G. (2018). Novel DNA Vaccine Formulations Against
Hepatitis C Virus. (PhD Thesis).

Year Citation
2025 Carolin, A., Bishop, C. R., Grubor-Bauk, B., Plummer, M. P., Raith, E., Barry, S. C., . . . Suhrbier, A. (2025). RNA-Seq of Nasopharyngeal Swabs from ICU Patients Infected with SARS-CoV-2 Omicron Sublineages in Adelaide, Australia, 2022–2023.
DOI
2024 Sinclair, J., Vedelago, C., Ryan, F., Carney, M., Lynn, M., Grubor-Bauk, B., . . . Short, K. (2024). Cardiovascular symptoms of PASC are associated with trace-level cytokines that affect the function of human pluripotent stem cell derived cardiomyocytes.
DOI Europe PMC2
2023 Perkins, G., Tunbridge, M., Chai, C. S., Hope, C., Yeow, A. E. L., Salehi, T., . . . Coates, T. (2023). mTOR inhibition improves the formation of functional T cell memory following COVID-19 vaccination of kidney transplant recipients.
DOI Europe PMC2
2023 Perkins, G., Hope, C., Chai, C. S., Tunbridge, M., Sterling, S., Webb, K., . . . Hissaria, P. (2023). Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy.
DOI
2021 Adhikari, A., Abayasingam, A., Rodrigo, C., Agapiou, D., Pandzic, E., Brasher, N., . . . Tedla, N. (2021). Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection.
DOI
2021 Ryan, F., Hope, C., Masavuli, M., Lynn, M., Mekonnen, Z., Lip Yeow, A. E., . . . Lynn, D. (2021). Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.
DOI Europe PMC1
2020 Bull, R., Abayasingam, A., Balachandran, H., Agapiou, D., Rodrigo, C., Keoshkerian, E., . . . Martinello, M. (2020). Long-term persistence of neutralizing memory B cells in SARS-CoV-2.
DOI

2019             B Grubor-Bauk, EJ Gowans, DK Wijesundara ($200,000) "A novel Zika virus DNA vaccine that provides complete protection from infection." Commercial Accelerator Scheme, Adelaide Enterprise, University of Adelaide and The Hospital Research Foundation

2019             B Grubor-Bauk "Barbara Kidman Women's Fellowship" ($60,000). University of Adelaide and The Hospital Research Foundation

2019             DK Wijesundara, EJ Gowans, S Robertson, B Grubor-Bauk, A Shrestha "A pre-clinical evaluation of an innovative DNA-based vaccination regimen to protect women of childbearing age against Zika virus during sexual transmission." Ch7 Children's Research Foundation and The Hospital Research Foundation ($200,000)

2018               Z Kopecki, B Grubor-Bauk, KA Fenix, D Wijesundara, A Cowin ($28,619) "Identification of a diagnostic marker for assessment and management  of psoriasis. New Adventures Fund UniSA and The Hospital Research Foundation 

2018                 EJ Gowans, B Grubor-Bauk, D Wijesundara, N Eyre ($88,000)  "HCV challenge studies in vaccinated mice’ . Australian Centre for HIV and Hepatitis Virology Research (ACH2).

2016-2018        EJ Gowans, B Grubor-Bauk, D Wijesundara. ($293,880):  A DNA vaccine for Zika virus. National Foundation for Medical Research and  Innovation (NFMRI)

2017                 EJ Gowans, B Grubor-Bauk, D Wijesundara ($85,000) A multigenotypic HCV DNA Vaccine. Australian Centre for HIV and Hepatitis Virology Research (ACH2)

2016-2017        EJ Gowans, B Grubor-Bauk, D Wijesundara ($100,000) "A DNA vaccine to induce protective neutralizing antibodies to the HIV Tat protein." The Hospital Research Foundation

2014                EJ Gowans, B Grubor-Bauk ($100,000) "Optimisation of HCV vaccine design."  The Hospital Research Foundation .

2014-2015        EJ Gowans, I Roberts-Thomson, B Grubor-Bauk ($300, 000). “DNA vaccine therapy for HCV.” The Hospital Research Foundation .

2012-2013        E.J. Gowans and B Grubor-Bauk 2012/2013 ($174,000) “Development of a cytolytic HCV vaccine and a novel challenge model to test efficacy.”  Australian Centre for HIV and Hepatitis Virology Research (ACH2).

Date Role Research Topic Program Degree Type Student Load Student Name
2024 Principal Supervisor Harnessing the potential of mRNA vaccines against Hepatitis C Virus Doctor of Philosophy Doctorate Full Time Mr John Henrik Johansson
2024 Principal Supervisor Harnessing the potential of mRNA vaccines against Hepatitis C Virus Doctor of Philosophy Doctorate Full Time Mr John Henrik Johansson
2023 Co-Supervisor The Effect of Sirolimus on Enhancing COVID-19 Vaccine Response in Transplant Recipients Doctor of Philosophy Doctorate Full Time Mr Cheng Sheng Chai
2023 Co-Supervisor The Effect of Sirolimus on Enhancing COVID-19 Vaccine Response in Transplant Recipients Doctor of Philosophy Doctorate Full Time Mr Cheng Sheng Chai
2022 Principal Supervisor A Trivalent Vaccine for Clinically-Important Flaviviruses. Doctor of Philosophy Doctorate Full Time Mr Ryan Santos
2022 Principal Supervisor A Trivalent Vaccine for Clinically-Important Flaviviruses. Doctor of Philosophy Doctorate Full Time Mr Ryan Santos
2021 Principal Supervisor The development of 'next generation' DNA-based vaccine against SARS-CoV-2 Doctor of Philosophy Doctorate Full Time Miss Zahraa Nima Saeed Al-Delfi
2021 Principal Supervisor The development of 'next generation' DNA-based vaccine against SARS-CoV-2 Doctor of Philosophy Doctorate Full Time Miss Zahraa Nima Saeed Al-Delfi
2021 External Supervisor Design of Lipid Nanoparticles (LNPs) for mRNA-Based Cancer Vaccines Doctor of Philosophy Doctorate Part Time Ms Mitra Hosseini Kharat

Date Role Research Topic Program Degree Type Student Load Student Name
2015 - 2016 Co-Supervisor Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus. Master of Philosophy (Medical Science) Master Full Time Mr Harshwardhan Jagdale
2015 - 2019 Co-Supervisor Pre-Clinical Evaluation of a Vaccination Strategy to Induce Liver Resident Memory T Cells against Hepatitis C Virus Doctor of Philosophy Doctorate Full Time Mr Zelalem Addis Mekonnen
2014 - 2018 Co-Supervisor Novel DNA Vaccine Formulations Against Hepatitis C Virus Doctor of Philosophy Doctorate Full Time Dr Makutiro Ghislain Masavuli
2013 - 2016 Co-Supervisor Novel Recombinant DNA and Live Virus Vaccines to Prevent or Control HIV-1 Infection Doctor of Philosophy Doctorate Full Time Mr Khamis Tomusange
2012 - 2014 Co-Supervisor Evaluating the Immuno-modulatory Effects of a Natural Adjuvant as a Novel Vaccine Strategy Doctor of Philosophy Doctorate Full Time Miss Tasmin Garrod
2012 - 2013 Co-Supervisor Optimising DNA vaccine technology to prevent HIV-1 Infection Doctor of Philosophy Doctorate Full Time Miss Tessa Gargett
2012 - 2017 Co-Supervisor The Development of a Multi-Antigenic Cytolytic DNA Vaccine against HCV Doctor of Philosophy Doctorate Full Time Dr Jason Anthony Gummow
2010 - 2012 Co-Supervisor Suicide Genes in a Novel Vaccination Strategy for Hepatitis C Master of Philosophy Master Full Time Mr Hugh Francis Trahair

Connect With Me

External Profiles

Other Links